We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Interaction of Cancer Stem Cells and the Tumor Microenvironment Regulates Growth and Progression of Ovarian Tumors

By LabMedica International staff writers
Posted on 16 Jan 2013
Recently published findings on the interaction of the growth factors Lin28, Oct4, and BMP4 unite two basic theories of how tumors develop and progress.

LIN28 is a marker of undifferentiated human embryonic stem cells and has been used to enhance the efficiency of the formation of induced pluripotent stem (iPS) cells from human fibroblasts. More...
It is a microRNA-binding protein that binds to and enhances the translation of the IGF-2 (insulin-like growth factor 2) mRNA. Lin28 has also been shown to bind to the let-7 pre-microRNA and block production of the mature let-7 microRNA in mouse embryonic stem cells. In pluripotent embryonal carcinoma cells, LIN28 is localized in the ribosomes, P-bodies, and stress granules.

BMP4 is a polypeptide belonging to the TGF-beta (transforming growth factor beta) superfamily of proteins. It, like other bone morphogenetic proteins, is involved in bone and cartilage development, specifically tooth and limb development and fracture repair. This particular family member plays an important role in the onset of endochondral bone formation in humans. It has been shown to be involved in muscle development, bone mineralization, and ureteric bud development.

Oct-4 (octamer-binding transcription factor 4) also known as POU5F1 (POU domain, class 5, transcription factor 1) is a protein that in humans is encoded by the POU5F1 gene. This protein is critically involved in the self-renewal of undifferentiated embryonic stem cells, and, as such, it is frequently used as a marker for undifferentiated cells.

Investigators at Yale University (New Haven, CT, USA) reported in the January 1, 2013, issue of the journal Cell Cycle that elevated production of BMPs from human ovarian cancer cells and stroma increased cancer stem cell proliferation and tumor growth. The stem cell factor Lin28 bound to BMP4 mRNA in epithelial ovarian carcinoma cells, thereby promoting BMP4 expression at the post-transcriptional level.

As coexpression of Lin28 and Oct4 (another stem cell factor) had been implicated in ovarian cancer stem cells, the investigators also determined that high levels of Lin28 were associated with an unfavorable prognosis when coexpressed with high levels of Oct4. Together, these findings uncovered a new level of regulation of BMP4 expression and implied a novel Lin28/Oct4/BMP4-mediated mechanism of regulating ovarian tumor cell growth, thus holding potential for the development of new strategies for the diagnosis and treatment of ovarian cancer.

The finding that Lin28 and Oct4 (both stem cell factors) regulated BMP-4 united two theories related to how cancer stem cells and the tumor microenvironment interact to promote tumor growth and progression.

"Ovarian cancer patients are plagued by recurrences of tumor cells that are resistant to chemotherapy, ultimately leading to uncontrolled cancer growth and death," said senior author Dr. Yingqun Huang, associate professor of obstetrics, gynecology, and reproductive sciences at Yale University. "These results are supported by the latest molecular ovarian cancer prognosis data, which also suggest an active role for the tumor microenvironment in ovarian carcinogenesis. "Together these studies reveal new targets for the development of cancer therapies."

Related Links:
Yale University


Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
Clinical Informatics Platform
CLARION™
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Characterization of EV separated by distinct methods (Photo courtesy of Yuanyuan Liu, Yanbin Guo et al. Engineering, doi.org/10.1016/j.eng.2025.12.009)

Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis

Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read more

Molecular Diagnostics

view channel
Image: NeoCircle Study Synopsis (George, A.M., Chen, Y., Gladchuk, S. et al. EMBO Molecular Medicine (2026). DOI: 10.1038/s44321-026-00447-z)

Ultrasensitive MRD Blood Test Detects Early Breast Cancer Recurrence

SAGA Diagnostics (Morrisville, NC, USA), a company specializing in tumor-informed, blood-based cancer detection and precision medicine, announced the publication of a new study evaluating its Pathlight... Read more

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.